Arovella Therapeutics Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • ALA

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $0.03
  • (As of Friday Closing)

Arovella Therapeutics General Information

Description

Arovella Therapeutics Ltd is engaged in the development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer. Its invariant Natural Killer T (iNKT) cell therapy platform is being developed as a next-generation, allogeneic off-the-shelf cell therapy platform with potential applications across blood cancers, solid tumours and selected autoimmune diseases. Its product, ALA-101, is a CD19-directed CAR-iNKT cell therapy for relapsed or refractory CD19- positive blood cancers. Arovella is expanding the platform into solid tumours through ALA-105, its CLDN18.2-targeting CAR-iNKT program for gastric and pancreatic cancers, and through incorporation of IL-12-TM armouring technology designed to enhance CARiNKT cell activity and durability.

Contact Information

Formerly Known As
Suda Pharmaceuticals, Eastland Medical Systems
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Corporate One
  • 84 Hotham Street
  • Preston, Victoria 3072
  • Australia
+61 (03)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • Corporate One
  • 84 Hotham Street
  • Preston, Victoria 3072
  • Australia
+61 (03)

Arovella Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arovella Therapeutics Stock Performance

As of 20-Nov-2026, Arovella Therapeutics’s stock price is $0.03. Its current market cap is $36.2M with 1.21B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.03 $0.03 $0.03 - $0.07 $36.2M 1.21B 699K

Arovella Therapeutics Financials Summary

As of 30-Sep-2026, Arovella Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 30,520 38,251 69,960 94,643
Revenue 88 11
EBITDA (5,148) (5,041) (5,789)
Net Income (4,685) (4,859) (5,732)
Total Assets 10,329 14,109 8,879
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Arovella Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Arovella Therapeutics‘s full profile, request access.

Request a free trial

Arovella Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Arovella Therapeutics Ltd is engaged in the development of its invariant Natural Killer T (iNKT) cell platform for the t
Drug Discovery
Preston, Australia
8 As of 2025

Toowong, Australia
 

Foster City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arovella Therapeutics Competitors (2)

One of Arovella Therapeutics’s 2 competitors is Kira Biotech, a Venture Capital-Backed company based in Toowong, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kira Biotech Venture Capital-Backed Toowong, Australia
Gilead Formerly VC-backed Foster City, CA
You’re viewing 2 of 2 competitors. Get the full list »

Arovella Therapeutics Patents

Arovella Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202103100-D0 Mitigating the off-target pharmacology of anagrelide in the treatment of thrombocytosis in various diseases Inactive 05-Mar-2021
AU-2016904449-A0 Mucosal active agent delivery Inactive 31-Oct-2016
AU-2017351744-A1 Mucosal active agent delivery Inactive 31-Oct-2016
CA-3041112-A1 Mucosal active agent delivery Inactive 31-Oct-2016
EP-3532068-A1 Mucosal active agent delivery Inactive 31-Oct-2016 A61K47/22
To view Arovella Therapeutics’s complete patent history, request access »

Arovella Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arovella Therapeutics Investments & Acquisitions (4)

Arovella Therapeutics’s most recent deal was a Corporate Asset Purchase with Aluztra Bio (Global Intellectual Property for Anagrelide). The deal was made on 01-Jan-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aluztra Bio (Global Intellectual Property for Anagrelide) 01-Jan-2018 Corporate Asset Purchase Buildings and Property
Novadel Pharma 13-Aug-2013 Merger/Acquisition Drug Delivery
Westcoast Surgical & Medical Supplies 30-May-2006 Merger/Acquisition Distributors (Healthcare)
Medical Industries Australia 22-Sep-2003 Merger/Acquisition Distributors (Healthcare)
To view Arovella Therapeutics’s complete investments and acquisitions history, request access »

Arovella Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Arovella Therapeutics’s complete esg history, request access »

Arovella Therapeutics Exits (2)

Arovella Therapeutics’s most recent exit was on 30-May-2006 from Westcoast Surgical & Medical Supplies. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Westcoast Surgical & Medical Supplies 30-May-2006 Completed
Medical Industries Australia 22-Sep-2003 Merger/Acquisition Completed
To view Arovella Therapeutics’s complete exits history, request access »

Arovella Therapeutics FAQs

  • When was Arovella Therapeutics founded?

    Arovella Therapeutics was founded in 1999.

  • Where is Arovella Therapeutics headquartered?

    Arovella Therapeutics is headquartered in Preston, Australia.

  • What is the size of Arovella Therapeutics?

    Arovella Therapeutics has 8 total employees.

  • What industry is Arovella Therapeutics in?

    Arovella Therapeutics’s primary industry is Drug Discovery.

  • Is Arovella Therapeutics a private or public company?

    Arovella Therapeutics is a Public company.

  • What is Arovella Therapeutics’s stock symbol?

    The ticker symbol for Arovella Therapeutics is ALA.

  • What is the current stock price of Arovella Therapeutics?

    As of 20-Nov-2026 the stock price of Arovella Therapeutics is $0.03.

  • What is the current market cap of Arovella Therapeutics?

    The current market capitalization of Arovella Therapeutics is $36.2M.

  • Who are Arovella Therapeutics’s competitors?

    Kira Biotech and Gilead are competitors of Arovella Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process